tadalafil + placebo + tadalafil + tadalafil + tadalafil + placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Impotence
Conditions
Impotence
Trial Timeline
Oct 1, 2002 → Sep 1, 2003
NCT ID
NCT00547508About tadalafil + placebo + tadalafil + tadalafil + tadalafil + placebo
tadalafil + placebo + tadalafil + tadalafil + tadalafil + placebo is a phase 3 stage product being developed by Eli Lilly for Impotence. The current trial status is completed. This product is registered under clinical trial identifier NCT00547508. Target conditions include Impotence.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00547508 | Phase 3 | Completed |
Competing Products
20 competing products in Impotence
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| tadalafil | Eli Lilly | Approved | 85 |
| tadalafil + sildenafil | Eli Lilly | Approved | 85 |
| GPI 1485 | Eisai | Phase 2 | 52 |
| tadalafil + sildenafil | Eli Lilly | Approved | 85 |
| tadalafil | Eli Lilly | Approved | 85 |
| tadalafil + sildenafil | Eli Lilly | Phase 3 | 77 |
| tadalafil | Eli Lilly | Phase 3 | 77 |
| tadalafil + placebo + tadalafil + tadalafil | Eli Lilly | Phase 3 | 77 |
| tadalafil + Placebo | Eli Lilly | Phase 3 | 77 |
| tadalafil + tadalafil + placebo | Eli Lilly | Phase 3 | 77 |
| tadalafil + tadalafil + placebo | Eli Lilly | Phase 3 | 77 |
| Fluvastatin-sodium | Novartis | Phase 3 | 77 |
| Sildenafil Citrate | Pfizer | Approved | 84 |
| UK0369,003 + Cialis (Tadalafil) | Pfizer | Phase 2 | 51 |
| Viagra (Sildenafil citrate) | Pfizer | Approved | 84 |
| sildenafil citrate | Pfizer | Approved | 84 |
| Placebo + Viagra (sildenafil citrate) | Pfizer | Approved | 84 |
| UK-369,003 | Pfizer | Phase 2 | 51 |
| Viagra (Sildenafil Citrate) 100 mg | Pfizer | Approved | 84 |
| Viagra (Sildenafil citrate) | Pfizer | Approved | 84 |